Patients who responded to T-VEC treatment showed an increase in CD8+ T cells, a high mutation load, and high expression of PD-L1 in several cell subgroups of the tumor, indicating that T-VEC followed by anti-PD-1 therapy can effectively decrease tumors that require the presence of specific T cells. The gene discussed is CD274; the disease is neoplasm.